Analyses of cohorts receiving GLP-1 receptor agonists, SGLT2 inhibitors, or structured training, with paired pre- and post-intervention biopsies, can identify reversible molecular programs in obesity and T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.